University of Buenos Aires

Horacio Sanchez-Granel Appointed President of NextGen International Insurance (NextGen i.i.)

Retrieved on: 
Wednesday, November 15, 2023
Professional Services, Health, Consumer, Insurance, Health Insurance, Finance, Hispanic, Risk management, National University of Rosario, University of Buenos Aires, Mechanical engineering, Nextgen, International Insurance Company, Education minister, University, Growth, Knowledge, Management

NextGen International Insurance (NextGen i.i.)

Key Points: 
  • NextGen International Insurance (NextGen i.i.)
  • is thrilled to announce the appointment of Mr. Horacio Sanchez-Granel as the new President and a member of the Board of NextGen i.i.
  • In a resounding endorsement of the recent appointment of Mr. Horacio Sanchez-Granel as President of NextGen International Insurance (NextGen i.i.
  • With the addition of Mr. Horacio Sanchez-Granel to its leadership team, NextGen i.i.

Renowned Artistic Director Maximiliano Guerra joins the team of Evergreen City Ballet Company

Retrieved on: 
Wednesday, December 13, 2023
Puget Sound region, Nutcracker, Student, Multimedia, Culture, Dance, Open House, ECB, Teatro, New York City Ballet, Bolshoi Ballet, English National Ballet, University of Buenos Aires, Entertainment, Management, Ballet

RENTON, Wash., Dec. 12, 2023 /PRNewswire-PRWeb/ -- Maximiliano Guerra is a celebrated director, choreographer, and educator, who has directed productions in various venues such as Teatro Colon and danced at English National Ballet, Bolshoi Ballet and La Scala. He has received numerous awards and accolades for his choreography and dancing, including the Konex Platinum Award and the Gold Medal International Ballet De Varna. He has taught courses on classical ballet, choreography, and staging at Buenos Aires University since 2014.

Key Points: 
  • As the artistic director of Evergreen City Ballet, Maximiliano Guerra now oversees the artistic vision and programming of the school, which is known for its innovative and diverse productions of classic and contemporary ballet.
  • "I am thrilled and honored to join Evergreen City Ballet as its new artistic director," said Guerra.
  • "We are delighted to welcome Maximiliano Guerra as our new artistic director," said Brian Wallace, President board of directors of Evergreen City Ballet.
  • Evergreen City Ballet was established in 1994 and received its non-profit status in 1995 as both a pre-professional ballet school and as a performing company.

Despegar.com Announces Organizational Changes

Retrieved on: 
Friday, March 3, 2023
Tourist Attractions, Vacation, Other Travel, Destinations, Travel, NYSE, Accounting, Interim management, Interim, COVID-19, University of Buenos Aires, Bachelor, Business administration, Cryptocurrency, Management

The Company’s Board of Directors has begun a search for a new Chief Financial Officer.

Key Points: 
  • The Company’s Board of Directors has begun a search for a new Chief Financial Officer.
  • In connection with Mr. Lopez Gaffney’s resignation, the Company also announced the appointment of Maria Bettina Zubin as Interim CFO.
  • Ms. Zubin has been the Company’s Controller since 2018 and brings almost 30 years of accounting and financial experience in positions of increasing responsibility at large global companies.
  • Ms. Zubin holds Bachelor degrees in Business Administration and Accounting from Buenos Aires University and an M.B.A. from CEMA University.

"Ukraine: past, present and future" an in-depth look at the Russian invasion of Ukraine one year after the start of the conflict

Retrieved on: 
Friday, February 24, 2023
Entertainment, Consumer, Film & Motion Pictures, TV and Radio, General Entertainment, Events, Concerts, Hispanic, Tombola, Reuters, University, Family, Daniel Viotto, Volodymyr Zelenskyy, UNICEF, State, United Press International, ICESI University, HITN, Point, Associate professor, University of Buenos Aires, Hope, World War II, Optimism, Life, Paulinum (University of Leipzig), Alice Salomon University of Applied Sciences Berlin, Imagination, Parent, Laboratory, Political science, Mobile phone, Arms industry, Communications satellite, Politics

Moderated by prominent Argentine journalist Daniel Viotto, the “Ukraine: past, present and future” forum will be broadcast simultaneously on HITN-TV, the HITNGo app and the network’s YouTube channel.

Key Points: 
  • Moderated by prominent Argentine journalist Daniel Viotto, the “Ukraine: past, present and future” forum will be broadcast simultaneously on HITN-TV, the HITNGo app and the network’s YouTube channel.
  • Director, Laboratory of Politics and International Relations (PoInt), and Associate Professor, Department of Political Studies, at Icesi University in Cali, Colombia.
  • “Ukraine: past, present and future” will simulcast on HITN-TV, the HITNGo app and the network’s YouTube channel from 9 p.m. to 10 p.m.
  • For more information on how to help those affected by the war in Ukraine, visit www.unicefusa.org/HelpUkraine .

Sensus Healthcare Announces Senior Management Appointments and Promotions

Retrieved on: 
Monday, January 9, 2023
Sentinel, Eclipse, Air force, Social media, Research, Information, Santa Clara University, Dermatology, Respect, University, San Jose State University, SCU Leavey School of Business, Business, Concordia University Texas, Quality assurance, Stetson University, Electroencephalography, Physics, Digital marketing, Second lieutenant, National university, Brain, Food and Drug Administration, Concordia University, Kyiv National University of Technologies and Design, Biology, Penn State Air Force ROTC, Marketing, Food, Growth, Moses Austin, Engineering, Patient, University of Buenos Aires, Intelligence, Software, Workforce, BOCA, Industrial, MBA, Regulation, Small business, GPS, Medical imaging, Management, Medical device, Cynosure, SensUs, Operation, EU

BOCA RATON, Fla, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, is pleased to announce the following promotions and appointments to its management team:

Key Points: 
  • BOCA RATON, Fla, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, is pleased to announce the following promotions and appointments to its management team:
    Ms. Martinez joined Sensus nine years ago and subsequently held positions of increasing responsibility.
  • Mr. Sosa joined Sensus last year as Vice President of Technology Development with extensive experience in banking, cyber security and artificial intelligence.
  • I am delighted to announce these promotions and appointments and look forward to the contributions of these talented individuals as Sensus executes on an aggressive business strategy,” said Joe Sardano, chairman and chief executive officer of Sensus Healthcare.
  • “Our goal is for Sensus to be a destination for great employees from all walks of life and backgrounds.

Ncardia and Cellistic recruit Gustavo Mahler to lead the businesses through their next phase of growth

Retrieved on: 
Thursday, January 5, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Management, IPSC, GMP, Doctor of Philosophy, Drug development, Multimedia, Norwest Venture Partners, MBA, AGC, Jethro Leadership Management Institute, Jian Wang (cellist), Growth, Investment, University, University of Buenos Aires, Charles III University of Madrid, MIT Sloan School of Management, Bayer, Sale, Biochemistry

Ncardia and Cellistic continue to build their leadership teams by recruiting Gustavo Mahler as Chief Executive Officer.

Key Points: 
  • Ncardia and Cellistic continue to build their leadership teams by recruiting Gustavo Mahler as Chief Executive Officer.
  • Gustavo was most recently a Venture Partner with DYNAMK Capital where he invested in leading life sciences tools, technologies, and services.
  • Prior to this role Gustavo spent ten years leading and growing CMC Biologics (now AGC Biologics) resulting in CMC’s sale to Asahi Glass Corporation for €520 million which created AGC Biologics.
  • “We are thrilled with the continued growth and expansion of Ncardia and Cellistic,” said Geoff Glass, Chairman of Ncardia and Cellistic.

Sapience Therapeutics Announces Appointment of Abi Vainstein-Haras, M.D. as Chief Medical Officer

Retrieved on: 
Thursday, December 1, 2022
Innovation, BioLineRx, Permeability, Drug, Peptide, Hematologic disease, MS, Teva, Glioblastoma, University, Cancer, IND, University of Buenos Aires, Therapy, Factor X, Patient, Running, Drug development, NDA, C/EBP, Multiple sclerosis, Phase II, CMO, Publication, Cytoplasm, Traffic barrier, PPI, Pharmaceutical industry, Vaccine, Wisdom, Spear

HARRISON, N.Y., Dec. 1, 2022 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, announced today the appointment of Dr. Abi Vainstein-Haras as Chief Medical Officer, effective December 1, 2022. Dr. Alice S. Bexon, who has served as a clinical advisor since 2017 and as Sapience's consulting Chief Medical Officer since 2019, will continue in an advisory role to support the transition to Dr. Vainstein-Haras and beyond. In addition, Dr. Bexon's clinical consulting group, Bexon Clinical, will continue to support the development of Sapience's clinical-stage pipeline and strategy. 

Key Points: 
  • HARRISON, N.Y., Dec. 1, 2022 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, announced today the appointment of Dr. Abi Vainstein-Haras as Chief Medical Officer, effective December 1, 2022.
  • "We are thrilled to welcome Abi to Sapience as Chief Medical Officer," commented Dr. Barry Kappel, CEO and President of Sapience.
  • She joins Sapience from BioLineRx, where she spent the last eight years serving in multiple roles of increasing responsibility, most recently serving as Chief Medical Officer sinceJanuary 2021.
  • "It has been my honor to serve as Chief Medical Officer of Sapience for the past three years," said Dr. Bexon.

GENOMMA LAB INTERNACIONAL ANNOUNCES LEADERSHIP SUCCESSION PLAN

Retrieved on: 
Monday, November 28, 2022
COVID-19, Culture, Growth, Government Model Senior Secondary School, Sector-16, Chandigarh, Mexican Stock Exchange, BMV, ESG, Mentorship, Disease, Commitment, Procter & Gamble, University, University of Buenos Aires, MM, Sustainability Accounting Standards Board, Premium, Brake, MEXICO, Behavior, Commercial, Active, Industrial engineering, Popular Executive Committee of Valencia, Management, Innovation

MEXICO CITY, Nov. 28, 2022 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, announces a leadership succession plan that positions the Company to continue driving profitable growth and delivering on the Company's vision, as CEO Jorge Brake has informed the Board of his intention to transition from the CEO role while maintaining active involvement in the Company's future. Mr. Brake will be appointed Active Vice Chairman of the Board of Directors, pending approval at Genomma's next Annual General Shareholders Meeting to be held in April 2023.

Key Points: 
  • In accordance with the Company's leadership succession plan, Mr. Rodrigo Herrera, Chairman of the Board informs that Marco Sparvieri, currently Genomma Lab's Chief Operating Officer, will succeed Jorge Brake as Chief Executive Officer.
  • Genomma's succession plan ensures a six month transition period during which Mr.
  • With a strong foundation and clear trajectory in place, now is the right time to implement our succession plan," said Brake.
  • Mr. Sparvieri joined Genomma Lab in 2014 after a successful 20 year career with Procter & Gamble, working in several geographies and roles.

Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and Symposium

Retrieved on: 
Monday, October 17, 2022
MIAMI, Immunology, University of Navarra, SEC, Therapy, Amyotrophic lateral sclerosis, Spinal cord, MS, Nerve, Autoimmune disease, Nobel Prize in Physiology or Medicine, Multiple sclerosis, Association of Environmental Engineering and Science Professors, National Academy of Sciences, RRMS, Optic nerve, Nobel Prize, NASDAQ, Neuroscience, Biotechnology, Psychopharmacology, Research, Program, ALS, Lists of diseases, Immunotherapy, University, Immune system, Immunization, Company, Department, Dana–Farber Cancer Institute, Neurology, CEO, University of Buenos Aires, Amyotrophy, CNS, GLOBE, Neurodegeneration, KTTA, Brain, DNA, Forward-looking statement, National academy, Noonan syndrome, Psychiatry, Central nervous system, Pharmaceutical industry, Medicine, Symposium

We look forward to presenting our data at an international forum with other world-renowned leaders in MS and immunotherapy, said Dr. Tiago Reis Marques, CEO, Pasithea.

Key Points: 
  • We look forward to presenting our data at an international forum with other world-renowned leaders in MS and immunotherapy, said Dr. Tiago Reis Marques, CEO, Pasithea.
  • The study results support the Companys ongoing commitment to the program and move us further along in our mission to uncover new and effective treatments for neurological disorders.
  • The field of neurology, particularly for disabling diseases such as MS, requires deep research into the nature of effective therapeutic and immunization solutions.
  • Pasithea Therapeutics is a biotechnology company primarily focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders.

Wyndham Hotels & Resorts Promotes Two Leaders to Executive Committee

Retrieved on: 
Thursday, October 13, 2022
Deloitte, RCI, NYSE, Executive Committee, Multimedia, University, Pennsylvania State University, Company, Industry, UADE, University of Buenos Aires, Certified Public Accountant, Super 8, Travel + Leisure Co., Wyndham Hotels & Resorts, Hotel, AmericInn

PARSIPPANY, N.J., Oct. 13, 2022 /PRNewswire/ -- Wyndham Hotels & Resorts, the world's largest hotel franchising company with approximately 9,000 hotels across more than 95 countries, has promoted Shilpan Patel to executive vice president, North America Franchise Operations, and Gustavo Viescas to president, LATAMC, and elevated both to the Company's Executive Committee effective immediately. With nearly 45 combined years, the two Company veterans have extensive experience helping Wyndham franchisees and owners around the globe succeed.

Key Points: 
  • With nearly 45 combined years, the two Company veterans have extensive experience helping Wyndham franchisees and owners around the globe succeed.
  • "A Wyndham core tenet is promoting from within thanks to our exceptional bench of leadership talent," said Geoff Ballotti, Wyndham Hotels & Resorts president and chief executive officer.
  • Gustavo has held multiple roles of increasing responsibility over his past 25 years with Wyndham leading the finance, administration, reporting, planning and operations for both RCI and Wyndham Hotels & Resorts.
  • Wyndham Hotels & Resorts (NYSE: WH) is the world's largest hotel franchising company by the number of properties, with approximately 9,000 hotels across over 95 countries on six continents.